Unregulated Melanotan I & II use linked to altered moles and emerging melanoma, review finds
Background
Synthetic alpha-melanocyte-stimulating hormone (α-MSH) analogues, known as melanotan I and melanotan II, have seen a rise in unregulated use, primarily for their ability to stimulate skin tanning. This trend is a concern for dermatologists who see patients engaged in a 'tanning culture'. While a regulated α-MSH analogue, afamelanotide, is approved and deemed safe for limited medical indications, the illegal versions are not. The lack of oversight for these unregulated compounds raises significant questions about their preparation, correct administration, and appropriate dosage, creating a potential public health risk that needs to be understood by both users and clinicians.
Study Design
This paper presents a review of existing literature and case reports to provide an overview of the risks associated with the unregulated use of synthetic α-MSH analogues. The authors synthesized information from case reports detailing cutaneous complications and melanoma emergence in users of melanotan I and melanotan II. They also examined the history and safety profile of the medically approved analogue, afamelanotide, as a point of comparison to highlight the dangers of the untested, illegal versions.
Results
The review identified a growing number of case reports associating unregulated melanotan I and melanotan II use with significant cutaneous complications. The primary concerns are melanocytic changes, including alterations in existing moles and the appearance of new, potentially dysplastic nevi. The most alarming finding is a documented link to skin cancer. > Four separate case reports have described melanomas emerging from pre-existing moles either during or shortly after the use of melanotan. Although the authors note that conclusive evidence directly causing these phenomena is not yet established, the association is strong enough that multiple national health organizations have issued public safety warnings regarding the use of these substances. The review contrasts this with the approved analogue, afamelanotide, which has been thoroughly tested and is considered safe for its specific medical indications.
Key Findings
- Unregulated use of melanotan I & II is associated with melanocytic changes in existing moles.
- Users have reported the emergence of new and potentially dysplastic nevi after using melanotan.
- Four specific case reports described melanomas emerging from existing moles during or shortly after melanotan use.
- Multiple national health organizations have issued safety warnings against melanotan I & II.
- The approved analogue, afamelanotide, has been tested and is deemed safe for limited medical indications, unlike illegal versions.
Why It Matters
This review serves as a critical warning to individuals participating in the 'tanning culture' who may consider using unregulated melanotan peptides. The key takeaway is that the cosmetic benefit of a tan may come with the severe risk of developing melanoma. For clinicians, particularly dermatologists, this highlights the importance of asking patients about their use of such substances when observing changes in nevi or diagnosing new skin lesions. The lack of regulation means users have no guarantee of purity, dosage, or safety, making any use a high-risk gamble. This research reinforces official warnings and stresses that until and unless these compounds undergo rigorous clinical trials and receive regulatory approval, they should be avoided. The evidence strongly suggests there is no safe protocol for using black-market melanotan.
